A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation...

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Clear cell renal cell carcinoma (ccRCC) recurrence risk after nephrectomy is typically assessed using clinical and pathological parameters.
• Personalized risk prediction can be enhanced by incorporating molecular tumor characteristics.
• Existing methods may not fully capture individual patient risk for recurrence.

Purpose of the Study:

• To develop and validate a prognostic multigene signature for predicting recurrence risk in ccRCC.
• To improve the accuracy and personalization of risk assessment for patients undergoing nephrectomy.
• To identify a molecular tool that complements existing prognostic factors.

Main Methods:

• A 16-gene recurrence score algorithm was developed using reverse-transcription PCR data from 942 ccRCC patients.
• Gene expression was analyzed for association with recurrence-free interval.
• The score was validated in an independent cohort of 626 ccRCC patients and analyzed using Cox regression.

Main Results:

• The recurrence score significantly correlated with recurrence-free interval and the risk of tumor recurrence in both univariate and multivariable analyses.
• A 25-unit increase in the score was associated with a 3.91-fold increased risk of recurrence (p<0.0001) in univariate analysis.
• The score effectively identified high-risk stage I and low-risk stage II-III ccRCC patients, with minimal intratumoural gene variability.

Conclusions:

• The validated recurrence score serves as a robust predictor of clinical outcomes in stage I-III ccRCC.
• This molecular signature provides a more accurate and individualized risk assessment compared to conventional parameters.
• The findings support the use of the recurrence score for personalized treatment strategies in ccRCC management.